Price movement over the last 24 hours
ARK Next Generation Internet ETF vs Novavax Inc — how do they compare? ARK Next Generation Internet ETF trades at $147, while Novavax Inc trades at $9.28 (market cap $1.53B). The key difference: Novavax Inc is trading nearer its 52-week high, ARK Next Generation Internet ETF nearer its low. Which is the better fit depends on your goals.
| ARKW | NVAX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $182.20 | $11.19 |
52-Week Low | $114.45 | $6.22 |
Market Cap | — | $1.53B |
Enterprise Value | — | $1.04B |
Signals from Pluang's Aura AI — not financial advice
ARKW trades at $148.42, down 0.75% with a bullish technical signal from moving averages. The ETF shows neutral momentum oscillators with RSI at 52.51 suggesting balanced buying pressure. Support levels are established at $144 and $142, while resistance sits at $147 and $148. Recent news highlights Cathie Wood's continued focus on innovative technology investments through her ETF strategies.
The ETF's exposure to disruptive innovation themes presents growth potential amid technology sector momentum. Key risks include concentration in high-growth tech stocks and market volatility sensitivity. Institutional interest remains strong given ARK Invest's track record in identifying transformative technologies.
Novavax (NVAX) trades at $9.33, down 0.74% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $14.00. The company reported revenue of $1.12 billion in 2025, swinging to a net income of $440.30 million, but faces negative cash flow and a negative shareholder equity position. Recent news highlights shareholder dissent at the AGM and investor attention amid vaccine stock volatility.
The outlook is mixed: strong valuation ratios and recent earnings beats suggest upside potential, but persistent cash burn and competitive pressures in the vaccine market pose significant risks. Analyst sentiment is predominantly bullish, yet the stock's performance remains sensitive to clinical developments and market sentiment toward biotech stocks.
Trailing returns across standard periods
ARKW is an actively managed ETF that invests in next-generation internet technologies. It focuses on cloud computing, AI, e-commerce, and blockchain innovation, with key holdings like Tesla, Advanced Micro Devices, and Roku.
Read more on ARKW →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →